AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|AAPL336.91+3.89 (+1.17%) ▲|ABBV256.91-2.45 (-0.94%) ▼|ABT104.49+1.43 (+1.39%) ▲|ACN154.06+7.07 (+4.81%) ▲|ADBE237.75+12.64 (+5.62%) ▲|AMAT516.89-19.36 (-3.61%) ▼|AMD494.95-27.00 (-5.17%) ▼|AMGN376.26+0.22 (+0.06%) ▲|AMT166.74+0.07 (+0.04%) ▲|AMZN231.39-0.72 (-0.31%) ▼|AVGO383.22+1.30 (+0.34%) ▲|AXP335.39+9.22 (+2.83%) ▲|BA211.50+1.98 (+0.95%) ▲|BAC62.13+0.08 (+0.13%) ▲|BKNG186.79+9.33 (+5.26%) ▲|BLK1,062.14+6.47 (+0.61%) ▲|BMY62.56+0.47 (+0.76%) ▲|BNY157.77-0.51 (-0.32%) ▼|BRK-B497.18+2.25 (+0.45%) ▲|C133.10+0.91 (+0.69%) ▲|CAT873.28-15.45 (-1.74%) ▼|CL91.98+1.23 (+1.36%) ▲|CMCSA22.80+0.51 (+2.27%) ▲|COF207.05+4.21 (+2.08%) ▲|COP115.58-4.68 (-3.89%) ▼|COST951.58+16.55 (+1.77%) ▲|CRM173.60+9.94 (+6.07%) ▲|CSCO114.57+0.40 (+0.35%) ▲|CVS107.07-0.67 (-0.62%) ▼|CVX190.00-4.79 (-2.46%) ▼|DE625.02-3.14 (-0.50%) ▼|DHR196.50+5.00 (+2.61%) ▲|DIS96.65+1.80 (+1.90%) ▲|DUK128.83-1.69 (-1.29%) ▼|EMR149.30+1.36 (+0.92%) ▲|FDX310.79-4.17 (-1.32%) ▼|GD389.14+2.39 (+0.62%) ▲|GE361.61+7.88 (+2.23%) ▲|GEV996.57-18.18 (-1.79%) ▼|GILD130.52+1.21 (+0.94%) ▲|GM87.04+4.40 (+5.32%) ▲|GOOG326.57+7.48 (+2.34%) ▲|GOOGL326.56+6.82 (+2.13%) ▲|GS1,048.23-13.00 (-1.23%) ▼|HD336.09+3.11 (+0.93%) ▲|HON245.75+2.60 (+1.07%) ▲|IBM216.28+2.09 (+0.98%) ▲|INTC91.67-0.65 (-0.70%) ▼|INTU303.91+7.58 (+2.56%) ▲|ISRG356.83+19.33 (+5.73%) ▲|JNJ265.95+2.55 (+0.97%) ▲|JPM356.20+2.99 (+0.85%) ▲|KO84.07+1.82 (+2.21%) ▲|LIN507.02-5.26 (-1.03%) ▼|LLY1,197.53+1.50 (+0.13%) ▲|LMT580.00-2.60 (-0.45%) ▼|LOW211.55+3.91 (+1.88%) ▲|LRCX291.61-13.60 (-4.46%) ▼|MA551.71+12.05 (+2.23%) ▲|MCD270.67+5.91 (+2.23%) ▲|MDLZ60.67+0.15 (+0.25%) ▲|MDT84.22+1.01 (+1.21%) ▲|META593.87-1.32 (-0.22%) ▼|MMM178.23+5.61 (+3.25%) ▲|MO72.89-0.10 (-0.14%) ▼|MRK130.76-0.31 (-0.24%) ▼|MS214.56+0.08 (+0.04%) ▲|MSFT389.10+7.40 (+1.94%) ▲|MU900.20-20.75 (-2.25%) ▼|NEE88.83-0.95 (-1.06%) ▼|NFLX70.40+0.31 (+0.44%) ▲|NKE42.14+0.44 (+1.06%) ▲|NOW105.56+6.78 (+6.86%) ▲|NVDA196.51-10.33 (-4.99%) ▼|ORCL119.90+4.91 (+4.27%) ▲|PEP139.79+3.15 (+2.31%) ▲|PFE24.67+0.13 (+0.53%) ▲|PG148.63+1.22 (+0.83%) ▲|PLTR131.53+8.61 (+7.00%) ▲|PM195.66+2.66 (+1.38%) ▲|QCOM170.04+3.07 (+1.84%) ▲|RTX218.42+5.63 (+2.65%) ▲|SBUX103.65+0.40 (+0.39%) ▲|SCHW104.18+2.21 (+2.17%) ▲|SO96.48-0.77 (-0.79%) ▼|SPG231.67+1.89 (+0.82%) ▲|T24.42+0.29 (+1.20%) ▲|TMO559.53-8.73 (-1.54%) ▼|TMUS177.21-2.88 (-1.60%) ▼|TSLA309.22-3.81 (-1.22%) ▼|TXN279.41-0.17 (-0.06%) ▼|UBER68.18+2.24 (+3.40%) ▲|UNH417.64-3.10 (-0.74%) ▼|UNP299.30-8.02 (-2.61%) ▼|UPS112.95-1.84 (-1.60%) ▼|USB63.49-0.48 (-0.75%) ▼|V362.53+6.79 (+1.91%) ▲|VZ47.32+0.94 (+2.03%) ▲|WFC87.27+0.96 (+1.11%) ▲|WMT111.74+2.27 (+2.07%) ▲|XOM154.77-2.17 (-1.38%) ▼|
22.6 C
New York
Tuesday, July 28, 2026

Tag: small cell lung cancer

newssourceFORcompanyinformationcontent1releasesmarket

Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell

— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI.— The Company is...

Eratrectinib, the next-generation TRK inhibitor independently developed by Vcare PharmaTech, has received marketing approval

NANJING, China, June 5, 2026 /PRNewswire/ -- NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors....

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic...

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsSmall cell lung cancer

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers